Eidos Therapeutics Inc (NASDAQ:EIDX) insider Jonathan C. Fox sold 5,000 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $23.11, for a total transaction of $115,550.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Eidos Therapeutics stock opened at $23.58 on Friday. The stock has a market capitalization of $859.22 million and a P/E ratio of -12.68. Eidos Therapeutics Inc has a 1 year low of $8.89 and a 1 year high of $25.55.

Eidos Therapeutics (NASDAQ:EIDX) last issued its quarterly earnings results on Monday, April 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.01). On average, analysts anticipate that Eidos Therapeutics Inc will post -1.3 earnings per share for the current year.

Several institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in shares of Eidos Therapeutics by 155.2% in the 4th quarter. Geode Capital Management LLC now owns 80,021 shares of the company’s stock worth $1,101,000 after acquiring an additional 48,659 shares in the last quarter. Wexford Capital LP grew its position in Eidos Therapeutics by 100.0% during the 4th quarter. Wexford Capital LP now owns 40,000 shares of the company’s stock valued at $550,000 after purchasing an additional 20,000 shares during the last quarter. Opaleye Management Inc. purchased a new stake in Eidos Therapeutics during the 4th quarter valued at about $1,926,000. Candriam Luxembourg S.C.A. purchased a new stake in Eidos Therapeutics during the 4th quarter valued at about $1,995,000. Finally, Hillhouse Capital Advisors Ltd. purchased a new stake in Eidos Therapeutics during the 4th quarter valued at about $2,458,000. Institutional investors own 30.15% of the company’s stock.

Several research analysts have commented on the stock. Zacks Investment Research lowered shares of Eidos Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, April 9th. BTIG Research assumed coverage on shares of Eidos Therapeutics in a report on Wednesday. They issued a “buy” rating and a $38.00 price objective for the company. JPMorgan Chase & Co. upgraded shares of Eidos Therapeutics from a “neutral” rating to an “overweight” rating in a report on Wednesday, February 27th. Finally, BMO Capital Markets assumed coverage on shares of Eidos Therapeutics in a report on Friday, February 22nd. They issued an “outperform” rating and a $28.00 price objective for the company. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Eidos Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $28.57.

COPYRIGHT VIOLATION WARNING: “Eidos Therapeutics Inc (EIDX) Insider Sells $115,550.00 in Stock” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2019/04/19/eidos-therapeutics-inc-eidx-insider-sells-115550-00-in-stock.html.

About Eidos Therapeutics

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

See Also: What are earnings reports?

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.